Interventional device developer Boston Scientific has submitted the final module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for its Taxus Liberté paclitaxel-eluting coronary sent system.
The third and final module contains nine-month data from the ATLAS clinical trial, according to the Natick, MA-based firm.
By AuntMinnie.com staff writers
March 9, 2006
Related Reading
Boston Scientific notifies EC of Guidant takeover, February 24, 2006
Boston Scientific shows 2005 sales gains, February 7, 2006
Boston Scientific raises Guidant offer, January 17, 2006
Abbott amends Boston Scientific agreement, January 17, 2006
Boston Scientific ups Guidant bid, January 13, 2006
Copyright © 2006 AuntMinnie.com